Gilead Sciences International, Ltd.

Gilead Sciences International, Ltd. is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative medicines. Established with a vision to improve the lives of patients worldwide, Gilead focuses on areas of unmet medical need, particularly in infectious diseases, oncology, and inflammatory diseases.

The company’s commitment to scientific excellence drives its extensive pipeline of therapies aimed at treating conditions such as HIV, hepatitis B and C, and various cancers. Gilead’s robust research initiatives are complemented by strategic partnerships with academic institutions and other organizations, fostering collaboration and innovation.

With a strong emphasis on patient-centricity, Gilead strives to ensure that its therapies are accessible to those who need them most. The company actively engages with healthcare professionals and communities to understand their needs and challenges, tailoring its solutions accordingly.

Core Values:

• Innovation: Pioneering new treatments through cutting-edge research.
• Integrity: Upholding the highest ethical standards in all operations.
• Collaboration: Working together with partners to enhance healthcare outcomes.
• Patient Focus: Prioritizing the needs and well-being of patients in every decision.

Headquartered in the UK, Gilead Sciences International, Ltd. operates globally, with a mission to transform the treatment landscape for serious diseases. The company is committed to sustainability and corporate responsibility, ensuring that its operations positively impact the communities it serves.

Through continuous investment in research and development, Gilead aims to remain at the forefront of medical advancements, ultimately striving to make a lasting difference in the lives of patients around the world.